Plain Packaging: What Real Impact on Sales and Prices?

Since the mid-2010s, cigarette packs have all started to look alike: the same dull brown, the brand name in small standardised type, and huge health warnings. This is plain packaging, or standardised packaging. Designed as a public health tool, it aims to make tobacco less appealing and to strip brands of their showcase. But what real effect has it had on sales and prices? The answer is nuanced, because plain packaging has almost never been introduced on its own.

What exactly is plain packaging?

Plain packaging is an pack from which every advertising element has been removed. In practice, it imposes several strict rules:

• A single, drab colour for all packs, usually a brown-green shade deemed unappealing.
• The removal of logos, brand colours and any distinctive graphic element.
• The brand name printed in a standardised font, size and position, identical for everyone.
• Large health warnings, often with shock images, covering most of the surface.

The idea is simple: a pack should never again serve as a marketing vehicle. All that remains is a product, its name and a reminder of its dangers.

The pioneer countries: Australia leads the way

Australia was the first country in the world to require plain packaging, in 2012. That decision, long challenged in the courts by the tobacco industry, served as a model and a laboratory on an international scale.

Other countries followed a few years later, notably France and the United Kingdom, then Ireland, Norway, New Zealand and several more. Today plain packaging has spread across a growing share of developed markets, often alongside sustained price increases.

The goal: breaking brand marketing

The stated aim of plain packaging is to reduce the appeal of the product, especially to younger people. By removing visual cues, it takes away one of tobacco's last communication spaces, at a time when direct advertising is already banned almost everywhere.

The pack also becomes a canvas for health warnings, now more visible than the brand name. The packaging, once an object of desire and loyalty, is turned into a simple reminder of the risks.

Plain packaging transforms the pack: from a tool of seduction, it becomes a permanent warning.

The observed effect on prevalence and perception

Studies carried out after the introduction of plain packaging, starting with those in Australia, show a real but modest effect: lower perceived appeal of packs, a heightened sense of the dangers, and a long-term decline in smoking.

Caution remains essential, however. Plain packaging has almost always been introduced alongside steep price increases and other anti-tobacco measures. It is therefore hard to isolate its own effect from that of price: the two act together, and the figures reflect the whole policy package more than the packaging alone.

The effect on brands and prices

By stripping brands of their visual identity, plain packaging triggers a kind of commoditisation: without a logo or distinctive colour, it becomes harder to justify a price gap through image. Competition then shifts toward the price itself.

Several observations suggest a rise of discount brands and downward pressure on premium segments, at least in theory. But this effect is largely masked by taxation: with taxes accounting for 70 to 80% of the price, the state sets most of the tag. A Marlboro pack sold for about €3.20 in France in 2000 exceeds €13 in 2026, and the United Kingdom remains the most expensive market at nearly €17. These increases stem first from excise duties, not from plain packaging.

Criticism and debates

The effectiveness of plain packaging remains disputed, first and foremost by the tobacco industry, which downplays its impact and sees it as an attack on brand property. Some also raise the risk of growing smuggling and counterfeiting, arguing that uniform packs are easier to copy.

Supporters of the measure point out that these arguments often come from interested parties, and that the decline in smoking seen in the pioneer countries remains consistent with the intended goals. The debate is therefore less about whether an effect exists than about its scale and how much of it is owed to the packaging versus the price.